CTI BioPharma Corp. (CTIC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CTI BioPharma Corp. (CTIC) trades at $9.10 with AI Score 56/100 (Grade B). CTI BioPharma Corp. is a biopharmaceutical company focused on developing and commercializing therapies for blood-related cancers. Market cap: $1.20B, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CTIC: CTIC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CTIC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CTIC: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
CTI BioPharma Corp. (CTIC) Healthcare & Pipeline Overview
CTI BioPharma Corp. specializes in targeted therapies for blood-related cancers, with VONJO as its primary offering. The company operates within the competitive biotechnology sector, focusing on the acquisition, development, and commercialization of novel treatments for myelofibrosis and other hematologic malignancies in the United States.
What Is the Investment Thesis for CTIC?
CTI BioPharma's investment thesis hinges on the commercial success of VONJO and its potential to capture a significant share of the myelofibrosis treatment market. With a market capitalization of $1.20B, the company's future growth depends on expanding VONJO's market reach and exploring new indications. The company's gross margin of 93.5% indicates strong pricing power, but the negative profit margin of -168.8% highlights the need for improved cost management. Upcoming catalysts include potential label expansions for VONJO and positive clinical trial results for other pipeline candidates. Key risks include competition from established therapies and potential regulatory hurdles.
Based on FMP financials and quantitative analysis
CTIC Key Highlights
- Market Cap of $1.20B reflects investor valuation of CTI BioPharma's potential in the myelofibrosis treatment market.
- Gross Margin of 93.5% indicates strong pricing power for VONJO.
- Negative P/E Ratio of -11.46 suggests the company is currently unprofitable, requiring careful monitoring of future earnings.
- Profit Margin of -168.8% highlights the need for improved cost management and increased sales to achieve profitability.
- Beta of 0.83 indicates lower volatility compared to the overall market.
Who Are CTIC's Competitors?
CTIC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CBIO Crescent Biopharma, Inc. | $15.05 | +2.03% | $415M | — |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| ETHZ ETHZ | $3.53 | +0.00% | $56.4M | 52 |
| GRCL Gracell Biotechnologies Inc. | $10.25 | +0.05% | $198M | 41 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| XERS Xeris Biopharma Holdings, Inc. | $8.60 | -2.27% | $1.48B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CTIC's Key Strengths?
- FDA-approved product (VONJO) for myelofibrosis treatment.
- Strong gross margin (93.5%).
- Experienced management team focused on hematologic malignancies.
- Strategic collaborations with Teva, S*BIO, and Baxalta.
What Are CTIC's Weaknesses?
- Negative profit margin (-168.8%).
- Reliance on a single product (VONJO) for revenue.
- Limited pipeline of additional drug candidates.
- High research and development expenses.
What Could Drive CTIC Stock Higher?
- Potential label expansion for VONJO to include earlier lines of myelofibrosis treatment (Timeline: 2027).
- Continued commercialization and market penetration of VONJO in the United States.
- Results from clinical trials evaluating VONJO in combination with other therapies (Timeline: 2026).
What Are the Key Risks for CTIC?
- Financial-distress signal — its Altman Z-Score of -27.07 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $2.6M recently.
- Competition from established therapies for myelofibrosis, such as Jakafi (ruxolitinib).
- Regulatory hurdles and delays in securing approvals for VONJO in new markets.
- High research and development expenses associated with developing new therapies.
- Unfavorable changes in reimbursement policies that could impact the pricing and market access of VONJO.
What Are the Growth Opportunities for CTIC?
- Expanding VONJO's Label: CTI BioPharma has the opportunity to expand VONJO's label to include earlier lines of myelofibrosis treatment and other related indications. This would significantly increase the addressable patient population and drive revenue growth. The market for myelofibrosis treatments is projected to reach $1.5 billion by 2028, offering substantial growth potential for VONJO.
- Strategic Partnerships: CTI BioPharma can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize VONJO in new markets. This would provide access to additional resources and expertise, accelerating the drug's global reach. Potential partners include companies with established oncology franchises and global distribution networks.
- Pipeline Expansion: CTI BioPharma can invest in expanding its pipeline of novel targeted therapies for blood-related cancers. This would reduce the company's reliance on VONJO and create new revenue streams. Potential pipeline candidates include drugs targeting other hematologic malignancies and novel therapeutic modalities.
- Real-World Evidence Generation: CTI BioPharma can generate real-world evidence (RWE) to support the clinical benefits of VONJO and differentiate it from competing therapies. This RWE can be used to support market access efforts and demonstrate the value of VONJO to payers and healthcare providers. RWE studies can focus on patient outcomes, quality of life, and cost-effectiveness.
- Geographic Expansion: CTI BioPharma can expand its geographic reach by commercializing VONJO in new markets outside the United States. This would require securing regulatory approvals in these markets and establishing distribution partnerships. Potential target markets include Europe, Japan, and other countries with significant unmet needs in myelofibrosis treatment.
What Opportunities Does CTIC Have?
- Expanding VONJO's label to include earlier lines of myelofibrosis treatment.
- Securing regulatory approvals for VONJO in new markets.
- Acquiring or licensing additional drug candidates to expand the pipeline.
- Partnering with larger pharmaceutical companies for co-development and commercialization.
What Threats Does CTIC Face?
- Competition from established therapies for myelofibrosis.
- Potential regulatory hurdles and delays.
- Patent expiration and generic competition.
- Unfavorable changes in reimbursement policies.
What Are CTIC's Competitive Advantages?
- Proprietary Drug: VONJO (pacritinib) is a patented drug with specificity for JAK2, FLT3, IRAK1, and CSF1R.
- Regulatory Exclusivity: VONJO benefits from regulatory exclusivity granted by the FDA.
- Specialized Expertise: CTI BioPharma has specialized expertise in the development and commercialization of therapies for blood-related cancers.
What Does CTIC Do?
CTI BioPharma Corp., founded in 1991 and headquartered in Seattle, Washington, is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative therapies for blood-related cancers. Originally named Cell Therapeutics, Inc., the company rebranded to CTI BioPharma Corp. in May 2014, reflecting its evolved strategic focus. The company's primary offering is VONJO (pacritinib), an oral kinase inhibitor targeting JAK2, FLT3, IRAK1, and CSF1R. VONJO is approved for the treatment of adult patients with myelofibrosis, a rare bone marrow cancer. CTI BioPharma operates primarily in the United States, collaborating with companies like Teva Pharmaceutical Industries Ltd., S*BIO Pte Ltd., and Baxalta to expand its research and development efforts. The company's focus on targeted therapies aims to provide improved treatment options for patients with hematologic malignancies, addressing unmet medical needs in this therapeutic area. CTI BioPharma's strategy involves both internal development and external partnerships to build a portfolio of novel cancer therapies.
What Products and Services Does CTIC Offer?
- Develop and commercialize targeted therapies for blood-related cancers.
- Offer VONJO (pacritinib) for the treatment of adult patients with myelofibrosis.
- Focus on acquiring novel cancer therapies.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Collaborate with other pharmaceutical companies to expand their research and development efforts.
- Seek regulatory approvals for their products from agencies like the FDA.
How Does CTIC Make Money?
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through the sale of VONJO.
- Collaborate with other companies through licensing and partnership agreements.
- Invest in research and development to expand their product pipeline.
What Industry Does CTIC Operate In?
CTI BioPharma operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for myelofibrosis treatments is growing, driven by an aging population and advancements in diagnostic techniques. Key competitors include companies developing alternative therapies for myelofibrosis and other hematologic malignancies. CTI BioPharma's success depends on its ability to differentiate VONJO from existing treatments and secure a significant share of the market.
Who Are CTIC's Key Customers?
- Adult patients diagnosed with myelofibrosis.
- Oncologists and hematologists who prescribe treatments for blood-related cancers.
- Hospitals and cancer centers that administer cancer therapies.
- Pharmacies that dispense prescription medications.
How CTI BioPharma Corp. Is Valued
CTI BioPharma Corp. carries a market capitalization of $1.20B, placing it in the small-cap category. Relative to its peer group, CTIC's quantitative score of 56/100 is roughly in line with the peer average of 47/100.
Company Profile
CTI BioPharma Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Adam R. Craig. CTIC has traded publicly since 1997.
Key Financial Metrics
Return on assets is -72.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
CTI BioPharma Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.07 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 12 insider filings for CTI BioPharma Corp. break down as 12 sales and 0 purchases. On net that is roughly 793K shares disposed (about $2.6M), a signal worth weighing alongside the fundamentals.
CTIC Financials
Bull Case vs Bear Case
Bull Case
- Community sentiment has shifted positively, with discussions highlighting the potential of their pipeline products.
- Recent clinical trial results have shown promise, boosting overall market perception of the company's innovation.
- Increased attention from institutional investors indicates a growing belief in the company's long-term viability.
Bear Case
- Concerns remain about the competitive landscape, with several companies advancing similar therapies that could overshadow CTI's offerings.
- Market sentiment has seen fluctuations, with some investors expressing skepticism about the pace of product development.
- Recent regulatory challenges could pose risks to the timely launch of key products, dampening investor enthusiasm.
- Overall economic uncertainty may lead to cautious sentiment among investors, impacting stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CTIC Latest News
No recent news available for CTIC.
CTIC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTIC.
Price Targets
Wall Street price target analysis for CTIC.
CTIC MoonshotScore
What does this score mean?
The MoonshotScore rates CTIC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Adam R. Craig
CEO
Adam R. Craig serves as the Chief Executive Officer of CTI BioPharma Corp. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and hematology. He has held leadership positions at various pharmaceutical companies, contributing to the development and commercialization of several cancer therapies. Craig's expertise spans clinical development, regulatory affairs, and commercial strategy. He is responsible for overseeing CTI BioPharma's strategic direction and driving the company's growth initiatives.
Track Record: Under Adam Craig's leadership, CTI BioPharma has achieved key milestones, including the FDA approval of VONJO for myelofibrosis treatment. He has focused on expanding the company's pipeline and strengthening its financial position. Craig has also overseen the implementation of strategic partnerships to support the commercialization of VONJO and the development of new therapies.
What Investors Ask About CTI BioPharma Corp. (CTIC) — Healthcare
What does the AI Score mean for CTIC?
CTIC holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. CTI BioPharma Corp. is a biopharmaceutical company focused on developing and commercializing therapies for blood-related cancers. Their key product is VONJO (pacritinib), an oral kinase inhibitor …
What does CTI BioPharma Corp. do?
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers. Its primary product is VONJO (pacritinib), an oral kinase inhibitor approved for the treatment of adult patients with myelofibrosis. The company aims to address unmet medical needs in hematologic malignancies by developing and commercializing innovative cancer therapies.
What do analysts say about CTIC stock?
Analyst consensus on CTIC stock is currently mixed, reflecting the company's reliance on a single product and its negative profit margin. Key valuation metrics include market capitalization and revenue growth potential. Analysts are closely monitoring the commercial performance of VONJO and the company's ability to expand its pipeline.
What are the main risks for CTIC?
The main risks for CTI BioPharma include competition from established therapies for myelofibrosis, such as Jakafi (ruxolitinib). Regulatory hurdles and delays in securing approvals for VONJO in new markets also pose a risk. High research and development expenses associated with developing new therapies can strain the company's financial resources.
What are the key factors to evaluate for CTIC?
CTI BioPharma Corp. (CTIC) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does CTIC data refresh on this page?
CTIC's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CTIC's recent stock price performance?
CTI BioPharma Corp. (CTIC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: FDA-approved product (VONJO) for myelofibrosis treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CTIC overvalued or undervalued right now?
CTI BioPharma Corp. (CTIC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CTIC before investing?
Before investing in CTI BioPharma Corp. (CTIC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on publicly available information and may be subject to change.
- Analyst opinions and ratings are based on third-party research and do not constitute investment advice.
- Forward-looking statements are subject to risks and uncertainties.